In vivo and in vitro studies have demonstrated that FEN1 is frequently overexpressed in various cancers, such as breast cancer, glioma, and hepatocellular cancer, and that its upregulation promotes tumorigenesis and cancer progression[47–50]. Here, FEN1 is linked to glioma.